C2 PHARMA Receives CEP approval for Timolol Maleate

Cork, Ireland — October 27, 2026 – C2 PHARMA, the global leader in ophthalmic active pharmaceutical ingredients (APIs), is pleased to announce that the European Directorate for the Quality of Medicines & HealthCare (EDQM) has granted a Certificate of Suitability (CEP) for Timolol Maleate.

This approval further strengthens C2 PHARMA’s ophthalmic portfolio and expands market access alongside its existing international registrations across key global markets. Regulatory authorities in numerous regions, including Asia-Pacific and other CEP-recognizing territories, may rely on the CEP within their approval pathways, broadening the availability of this important API worldwide.

Timolol Maleate is a well-established non-selective beta-adrenergic blocker widely used in ophthalmic formulations to reduce elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Recognized as a cornerstone of glaucoma therapy for decades, it remains an essential ingredient in both single-agent and fixed-combination eye drops that help preserve patients’ vision.

The addition of a CEP for Timolol Maleate reflects C2 PHARMA’s continued commitment to delivering reliable, high-quality solutions for essential eye care treatments. With one of the industry’s most comprehensive ophthalmic API portfolios, C2 PHARMA continues to support partners worldwide through regulatory excellence, supply security and specialized market expertise.